11 pages. "This preliminary observational study of real-world data suggests that increased GLP-1 adherence may lower the medical cost of care for an expanding number of chronic conditions; however, this does not offset the cost of the GLP-1 medications.... Although it may be too early to determine the true impacts of GLP-1 and GLP-1/GIP medications on the overall total cost of care, creating the analytic framework to monitor emerging trends can identify potentially actionable opportunities to re-evaluate care intensity for conditions influenced by GLP-1 drugs."  MORE >>